跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2008-003960-20-ES
EUCTR2008-003960-20-ES进行中（未招募）不适用

Ensayo multicéntrico, abierto, no controlado sobre la eficacia y la seguridad de N8 en la prevención y el tratamiento a demanda de los episodios hemorrágicos en sujetos con hemofilia A previamente tratadosSubestudio:Eficacia y seguridad de N8 en la prevención y el tratamiento de la hemorragia durante los procedimientos quirúrgicos en sujetos con hemofilia AEfficacy and Safety of N8 in Prevention and On-demandTreatment of Bleeding Episodes in Previously TreatedSubjects with Haemophilia ASub-Trial:Efficacy and Safety of N8 in Prevention and Treatmentof Bleeding during Surgical Procedures in Subjects withHaemophilia A

ovo Nordisk A/S0 个研究点目标入组 140 人开始时间: 2009年5月21日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
140
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • •1. Completion of the phase 1 PK trial NN7008-3522
  • •2. Informed consent obtained prior to any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)
  • •3. Male subjects with the diagnosis of severe (baseline FVIII?1%) haemophilia A from age 12 to 56 years having a weight of 10 to 120 kg.
  • •4. Willing to undergo a bleeding preventive regimen of 75 exposure days
  • •5. Non-bleeding state (i.e. no clinical manifestation of active bleed) at the time of administration of trial product for measurement of recovery in relation to administration of the first dose and the PK session
  • •6. Documented history of at least 150 exposure days to any other FVIII products (prevention or on-demand treatment) (Please refer to section 8.6.2.3)
  • •7. No history of FVIII inhibitors ?0.6 BU/mL measured regularly since the first treatment of haemophilia A prior to entering the trial or the time period should cover at least 8 years (Please refer to section 8.6.2.2)
  • •8. No detectable inhibitors to FVIII ( ?0.6 BU/mL) (as assessed by central laboratory at the investigative site at the time of screening)
  • •9. Hepatitis C Virus (HCV) seronegative or if HCV seropositive, viral load <200.000 IU/mL and CD4+ lymphocyte count ? 200/µL.
  • •10. Lupus anticoagulant negative
  • •11. HIV-1 seronegative or if HIV-1 seropositive, the viral load <400.000 copies/mL and the CD4+ lymphocyte count ?200/µL.
  • •1. Informed consent obtained prior to any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject).
  • •2.Male subjects with the diagnosis of severe (baseline FVIII?1%) haemophilia A from age 12 to 65 years having a weight of 10 to 120 kg.
  • •3. Willing to undergo a bleeding preventive regimen of 75 exposure days 4. Non-bleeding state (i.e. no clinical manifestation of active bleed) at the time of administration of trial product for measurement of recovery in relation to administration of the first dose
  • •5. Documented history of at least 150 exposure days to any other FVIII products (prevention or on-demand treatment) (Please refer to section 8.6.2.3)
  • •6. No history of FVIII inhibitors ?0.6 BU/mL measured regularly since the first treatment of haemophilia A prior to entering the trial or the time period should cover at least 8 years (Please refer to History of Inhibitors in section 8.6.2.2)
  • •7. No detectable inhibitors to FVIII ( ?0.6 BU/mL) (as assessed by central laboratory at the time of screening)
  • •8. HCV seronegative and or if HCV seropositive, viral load <200.000 IU/mL and CD4+ lymphocyte count ? 200/µL.
  • •9. Lupus anticoagulant negative
  • •10. HIV-1 seronegative or if HIV-1 seropositive, the viral load <400.000
  • •copies/mL and the CD4+ lymphocyte count ?200/µL.
  • •12.Scheduled to undergo major or minor surgical procedures
  • •13.Surgical procedure requiring at least 6 days of infusion of N8 concentrate post-operatively.
  • •Subjects will only participate in Part C when they have been included in either Part A or Part and have received at least one dose of trial product (N8).
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1. Subjects on Immune Tolerance Treatment (ITT) regimens
  • •2.Pharmaceutical treatment of a mild and moderate bleeding episode within one week prior to first dose
  • •3. Pharmaceutical treatment of a severe bleeding episode within one week prior to first dose
  • •4. Known pseudo-tumours
  • •5. Platelet count <50,000 platelets/µL (based on medical records) at trial entry
  • •6. Severe current hepatic dysfunction or severe hepatic disease during the last 12 months
  • •7. ALAT > than 4 times of the upper limit of normal reference range (as defined by central laboratory ranges
  • •8. Septicaemia, e.g. febrile illness within 5 days prior to trial product administration
  • •9. Current dialysis therapy
  • •10. Creatinine levels 50% above normal level (according to central laboratory range)
  • •11. Congenital or acquired coagulation disorders other than haemophilia A
  • •12. Previous arterial thrombotic events (Myocardial Infarction and Intra Cranial Thrombosis) (as defined by medical records).
  • •13. Known or suspected allergy to trial product (N8) or related products
  • •14. Surgery within one month prior to first administration of trial product (catheter, stents, ports, and dental extractions do not count as surgeries, i.e. they will not exclude the subject)
  • •15. Use of Coagulation Factors: FVIII concentrates or other FVIII containing products within four days prior to first administration of trial product
  • •16. Use of Anticoagulants: Heparin, vitamin-K antagonists, and direct thrombin inhibitors one week prior to first administration of trial product
  • •17. Use of non-prescribed opiate substances
  • •18. Regular use of cannabis (only for subjects in Part A)
  • •19. Use of platelet inhibitors including NSAID one week prior to first administration of trial product
  • •20. The receipt of any investigational drug within 30 days prior to administration of trial product except subjects who have completed NN7008-3522
  • •21. Previous participation in the current trial (defined as withdrawal) or withdrawn subjects from NN7008-3522 after administration of trial product
  • •22. Any disease or condition which, according to the Investigator?s judgement, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome
  • •23. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

研究者

相似试验

进行中（未招募）
1 期
Ensayo abierto, multicéntrico y no controlado para investigar la pauta de administración de degarelix una vez al mes como privación intermitente de andrógenos durante un ciclo de tratamiento en pacientes con cáncer de próstata que requieren tratamiento de privación androgénica.An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy. - FE200486CS29Cáncer de próstata.Prostate Cancer.
EUCTR2008-003931-19-ESFerring Pharmaceuticals A/S200
进行中（未招募）
1 期
Estudio multicéntrico, abierto, no controlado para investigar la eficacia y seguridad del parche anticonceptivo transdérmico que contiene 0,55 mg de etinilestradiol y 2,1 mg de gestodeno (n.º de material 80876395) en una pauta de 21 días durante 13 ciclos en 1650 mujeres sanas Multi-center, open-label, uncontrolled study to investigate the efficacy and safety of the transdermal contraceptive patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen for 13 cycles in 1650 healthy female subjects - Estudio UE/LA/AUS Índice de Pearl - Parche anticonceptivo transdérmico
EUCTR2008-004214-27-ESBayer Healthcare AG
进行中（未招募）
不适用
Ensayo multicéntrico, abierto, aleatorizado, controlado, de 24 meses de duración para evaluar la eficacia, seguridad y evolución de los parámetros cardiovasculares en pacientes receptores de un trasplante renal de novo después de la conversión temprana de un inhibidor de la calcineurina a everolimus - ELEVATETrasplante renalMedDRA version: 11Level: PTClassification code 10038533Term: Trasplante renal
EUCTR2009-015918-22-ESovartis Farmacéutica, S.A.676
进行中（未招募）
不适用
Estudio abierto, no controlado, multicéntrico, de fase II para estudiar la eficacia y seguridad de una combinación de Capecitabina + Bevacizumab, en 1ª línea de tratamiento, en pacientes ancianos no susceptibles de poliquimioterapia con adenocarcinoma colorrectal avanzado o metastático - BECA
EUCTR2005-002808-42-ESGRUPO ONCOPAZ
进行中（未招募）
不适用
Ensayo abierto, no aleatorizado, multicéntrico, que evalúa la eficacia y seguridad de deferasirox (Exjade®) en pacientes con sobrecarga férrica después de un trasplante alogénico de progenitores hematopoyéticos
EUCTR2008-003207-30-ESOVARTIS FARMACEUTICA S.A